本公司新藥Elixcyte®用以治療膝骨關節炎之第1、2期臨床試驗，業已取得衛福部同意備查函，未來將諮詢相關必要單位進行後續臨床試驗之規劃。
Elixcyte, a new cellular therapeutic treating OA knee developed by Unicocell, has completed the Phase I/II clinical trial with positive acclaim. The preparation of more comprehensive efficacy studies are intensively undertaking.